Recent studies have converged on the overlap of glucagon-like peptide-1|GIP|GCGR activator therapies and DA communication. While GCGR stimulators are increasingly employed for managing type 2 diabetes mellitus, their potential effects on reinforcement circuits, specifically influenced by DA networks, are receiving substantial attention. This paper